SERB Pharmaceuticals
SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth
May 30, 2024 07:00 ET | BTG Specialty Pharmaceuticals
Philadelphia, PA, May 30, 2024 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, has appointed Vanessa Wolfeler as its new Chief Executive Officer (CEO) effective...
Largest study to dat
Largest study to date of high-dose methotrexate associated acute kidney injury supports the use of Voraxaze® (glucarpidase)
December 11, 2023 09:51 ET | BTG Specialty Pharmaceuticals
West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX)...
BTG Pharmaceuticals,
BTG Pharmaceuticals, a SERB company, to present data on ricin antidote development programme at the North American Congress of Clinical Toxicology
September 21, 2023 06:42 ET | BTG Specialty Pharmaceuticals
West Conshohocken, PA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announced today that SERB will present in vivo data for PR022, a polyclonal antibody in development as...
BTG Pharmaceuticals
BTG Pharmaceuticals Statement on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Use of Glucarpidase (Voraxaze®) and MTXPK.org
June 22, 2023 08:28 ET | BTG Specialty Pharmaceuticals
West Conshohocken, PA, June 22, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute...
New Publication Comp
New Publication Compares Total Vials of CroFab® and Anavip® Administered to Treat US Rattlesnake Envenomation
May 02, 2023 08:12 ET | BTG Specialty Pharmaceuticals
West Conshohocken, PA, May 02, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, today announced the publication of a new analysis of data from the American College of Medical...
New economic analysi
New economic analysis of Voraxaze® (glucarpidase) in patients with delayed methotrexate
March 15, 2023 09:58 ET | BTG Specialty Pharmaceuticals
West Conshohocken, PA, March 15, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, today announces the publication of an economic simulation assessing the value of Voraxaze®...
SERB Pharmaceuticals
SERB Pharmaceuticals licenses Soligenix antigen to develop ricin antidote
July 14, 2022 07:01 ET | BTG Specialty Pharmaceuticals
Philadelphia, July 14, 2022 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals has signed a worldwide exclusive license to use an antigen from Soligenix [NSDQ: SNGX] to develop a novel therapeutic treatment...
Four Independent Stu
Four Independent Studies of Voraxaze® Published at European Hematology Conference 2022
June 09, 2022 04:49 ET | BTG Specialty Pharmaceuticals
Vienna, June 09, 2022 (GLOBE NEWSWIRE) -- The European Hematology Association (EHA) Conference published four independent studies of Voraxaze® (glucarpidase) by various investigators for inclusion...
Thomas Kolaras
Thomas Kolaras Joins SERB and BTG Specialty Pharmaceuticals as US Chief Commercial Officer
April 11, 2022 07:10 ET | BTG Specialty Pharmaceuticals
Philadelphia, April 11, 2022 (GLOBE NEWSWIRE) -- SERB and BTG Specialty Pharmaceuticals are pleased to announce that Thomas Kolaras has been named the group’s new Chief Commercial Officer for its US...
SERB acquires the ri
SERB acquires the rights to Xermelo® outside US and Japan for Carcinoid Syndrome Diarrhoea
April 04, 2022 02:08 ET | BTG Specialty Pharmaceuticals
Paris, April 04, 2022 (GLOBE NEWSWIRE) -- SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US...